Physician profile
Benjamin Collard
NPI 1750941126
$674.71
in general payments reported to CMS, 2019-2025
13 companies · $86.07 in 2025
The $86.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.47 · 2023: $126 · 2024: $433 · 2025: $86.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.57 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $99.38 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $76.88 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $65.12 | 2025 | Zepbound |
| Amgen INC. | $59.55 | 2023-2024 | Otezla, Repatha |
| Kvk-Tech, INC. | $48.25 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $36.80 | 2023-2024 | Eliquis |
| Dexcom, INC. | $23.54 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $20.58 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $17.40 | 2023 | Zilretta, Iovera, Exparel |
| Novartis Pharmaceuticals Corporation | $15.42 | 2022 | |
| Abbvie INC. | $14.17 | 2023 | Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Collard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.